Work

Vectored ImmunoProphylaxis with VRC07 Protects BLT Humanized Mice from Vaginal Transmission of Founder HIV

Year: 2013

Type: article

Abstract: Recently, a number of antibodies capable of broadly \nneutralizing HIV have been isolated from HIV infected patients, \nstimulating efforts to elicit their production in naive individuals. \nAs an alternative to vaccination, we recently described vectored \nimmunoprophylaxis (VIP) as an approach capable of generating \nhigh serum concentrations of a desired monoclonal antibody in \nmice following a single intramuscular injection of a specialized \nadeno associated viral vector (AAV). Mice that received VIP encoding \nb12, VRC01 or VRC07 antibodies demonstrated long-term \ncirculating antibody expression in serum, and VIP-treated humanized \nmice exhibited remarkable protection against high dose, \nintravenous challenge with CXCR4-tropic HIV. However, most \nhuman infections are initiated by transmission of CCR5-tropic \nstrains through mucosal tissues.

Source: CaltechAUTHORS (California Institute of Technology)

DOI: 10.1089/aid.2013.1500

Authors: Balazs, A. B., Yong, O., Hong, C. M., Chen, J., Rao, D. S., An, D., Baltimore, D.

Institutions: California Institute of Technology, Beth Israel Deaconess Medical Center, University of California, Los Angeles, Duke University

Language: English

Topic: HIV Research and Treatment

Subfield: Virology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W1641237748

FWCI:

Cites:

Cited by:

Related to: 20